BIOMX INC (PHGE)

US09090D1037 - Common Stock

0.45  +0.09 (+26.37%)

After market: 0.4187 -0.03 (-6.96%)

News Image
a day ago - BiomX

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage...

News Image
10 days ago - Telum Therapeutics

Telum Therapeutics appoints Dr. Subhendu Basu as CEO

/PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel...

News Image
10 days ago - BiomX

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary...

News Image
20 days ago - Chartmill

Stay updated with the stocks that are on the move in today's after-hours session.

Which stocks are moving after the closing bell on Friday?

News Image
22 days ago - InvestorPlace

Why Is BiomX (PHGE) Stock Up 147% Today?

BiomX stock is rocketing higher on Wednesday with heavy trading of PHGE shares after announcing a new merger agreement.

News Image
22 days ago - BiomX

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in...

News Image
4 months ago - Seeking Alpha

BiomX files for $150M mixed shelf (NYSE:PHGE)

BiomX (PHGE) files a prospectus for a mixed securities shelf offering of up to $150M.

News Image
4 months ago - BiomX

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage...

News Image
4 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning!

News Image
4 months ago - BiomX

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV11 and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory...

News Image
5 months ago - BiomX

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month BX004 received FDA Fast Track...

News Image
5 months ago - BiomX

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage...

News Image
5 months ago - BiomX

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing...

News Image
6 months ago - BiomX

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Company remains on track to report Part 2 results from the study in November 2023 Part 1 data of the Phase 1b/2a study accepted for oral presentation at...

News Image
7 months ago - BiomX

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage...

News Image
8 months ago - BiomX

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grants BX004 Fast...

News Image
8 months ago - BiomX

BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage...

News Image
10 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!

News Image
10 months ago - BiomX

NYSE American Initiates Delisting Proceedings for BiomX Warrants

Shares of the Company’s common stock and units (PHGE and PHGE.U) are unaffected by delisting proceedings of warrants and will remain trading on NYSE...

News Image
10 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning!

News Image
10 months ago - BiomX

BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage...

News Image
11 months ago - BiomX

BiomX Reports First Quarter 2023 Financial Results and Provides Business Update

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”); Results from Part...

News Image
a year ago - BiomX

BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage...

News Image
a year ago - InvestorPlace

Why Is BiomX (PHGE) Stock Up 10% Today?

BiomX (PHGE) stock is on the rise Friday as investors prepare for the clinical-stage company to release its latest earnings report on Monday.

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time for another dive into the biggest pre-market stock movers traders need to know about as we cover the winners and losers for Friday!